Stay updated on ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 with no visible changes to study details or trial information.
    Difference
    0.0%
    Check dated 2026-03-06T18:07:10.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Results posting information was added (Results First Posted 2026-02-17; Results First Submitted 2024-03-25), and the study now includes Exploratory Arm 1 and 2 as well as Arm B (RP2D) with related dosing details.
    Difference
    6%
    Check dated 2026-02-20T09:44:24.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The revision label on the page updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-13T03:43:02.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The page shows a minor site revision from v3.4.0 to v3.4.1; no changes to study content or navigation are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T12:19:26.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page shows a new revision tag 'Revision: v3.3.4' replacing the previous 'Revision: v3.3.3', a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T03:06:24.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Locations information was updated: a new Locations section lists Florida, Minnesota, Ohio, and South Carolina, with the previous state entries removed; the HHS Vulnerability Disclosure link was also removed.
    Difference
    0.5%
    Check dated 2025-12-24T12:21:13.000Z thumbnail image

Stay in the know with updates to ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.